FIRST: Serum Institute gets DCGI nod for qHPV vaccine against cervical cancer

The National Technical Advisory Group on Immunisation (NTAGI) had recently also approved the qHPV after reviewing the clinical trial data of the vaccine.

Published On 2022-07-13 06:07 GMT | Update On 2024-02-15 17:16 GMT

New Delhi: India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India's (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).The Serum Institute of India's CEO Adar Poonawalla tweeted to make the announcement. "For the first time, there will be an Indian HPV vaccine...

New Delhi: India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India's (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).

The Serum Institute of India's CEO Adar Poonawalla tweeted to make the announcement. "For the first time, there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the DCGI, MoHFW_INDIA for granting approval today," it read.

The National Technical Advisory Group on Immunisation (NTAGI) had recently also approved the qHPV after reviewing the clinical trial data of the vaccine.

Read also: Include Cy-Tb injection in national TB elimination programme: SII urges MoHFW

The Subject Expert Committee on June 15 recommended Serum Institute of India (SII)'s indigenously developed Quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer for regular market authorisation.

The phase 3 data of the vaccine was found satisfactory after which recommendations were made.

Read also: DCGI recommends allowing SII to manufacture, stockpile life-saving qHPV vaccine against cervical cancer

Sources close to ANI said, "It is expected that vaccine will be launched in the market before the year-end. The qHPV will be India's first indigenously vaccine against cervical cancer. The Pune-based Serum Institute of India has applied for market authorisation after completing the phase 2/3 clinical trial with the support of the Department of Biotechnology to ensure its early availability in the country."

On June 15, the DCGI's Subject Expert Committee recommended Serum Institute's indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients above 9 years to 26 years of age.

Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide and about 311 000 women died from the disease.

Read also: CDSCO panel recommends market nod for Serum Institute qHPV vaccine against cervical cancer

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

FIRST: Serum Institute gets DCGI nod for qHPV vaccine against cervical cancer

The National Technical Advisory Group on Immunisation (NTAGI) had recently also approved the qHPV after reviewing the clinical trial data of the vaccine.

Similar News